CoreAge Rx vs Navio MD
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Navio MD head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 77 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Navio MD a bad call — it's best for readers comparing advertised compounded and brand routes who will obtain the complete payment and commercial terms before starting. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Navio MD |
|---|---|---|
| Brief Score | 94/100 (A) | 77/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm current medication quote Earlier starting brand quote: $345/mo. Current semaglutide availability and full price require confirmation. Full price detailsCurrent medication quote unknown; earlier observed from $345/month for starting-dose brand semaglutide |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Confirm full upfront quote Compounded tirzepatide advertised from $189/mo; full upfront charge, term and renewal remain unclear. Full price detailsCompounded tirzepatide offered. Current complete quote unknown; earlier observed from $189/month for starting-dose compounded tirzepatide |
| Coverage | US only; restrictions by state, confirmed at intake | Medication-specific state availability requires confirmation |
| Brand-name access | Not confirmed | Yes |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Navio MD: Current complete prices remain unconfirmed. The $189 compounded tirzepatide and $445 Zepbound starting offers require the selected plan, upfront charge and renewal terms to be clarified.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.